Beijing Biostar Pharmaceuticals Co., Ltd. (BIOSTAR PHARM-B, 02563) will convene a board meeting on 25 March 2026 in Beijing to address three core agenda items:

1. Approval and publication of the consolidated annual results for the financial year ended 31 December 2025. 2. Consideration of a final dividend recommendation for shareholders. 3. Handling of other routine corporate matters.

The meeting will be chaired by Dr. Tang Li, who serves as Chairman and Executive Director. The current Board comprises nine members, including four executive directors, two non-executive directors and three independent non-executive directors.

The company released the meeting schedule through an official announcement dated 11 March 2026, in accordance with Hong Kong listing requirements.